Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat Mesylate vs Citrate Anticoagulation for CRRT in Sepsis-Associated AKI
NCT07518303Phase 4Not yet recruiting
- Sponsor
- Jianfeng Xie
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of Nafabelltan in sepsis-associated acute kidney injury (S-AKI), sponsored by Jianfeng Xie. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Nafabelltan
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on NCT07518303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518303.